Torrent Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 2 February 2024, inter alia, have recommended the interim dividend of Rs 22 per equity Share (i.e. 440%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Net profit of Torrent Pharmaceuticals rose 51.71% to Rs 443.00 crore in the quarter ended December 2023 as against Rs 292.00 crore during the previous quarter ended December 2022. Sales rose 9.43% to Rs 2691.00 crore in the quarter ended December 2023 as against Rs 2459.00 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales2691.002459.00 9 OPM %32.2929.44 - PBDT756.00612.00 24 PBT543.00419.00 30 NP443.00292.00 52 Powered by Capital Market - Live News

Torrent Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 2 February 2024.Powered by Capital Market - Live News

Torrent Pharmaceuticals announced that the USFDA conducted a pre-approval inspection at the company`s oral oncology manufacturing unit situated at Bileshwarpura, Gujarat from 05 December 2023 to 11 December 2023.At the end of the inspection, the company was issued a Form 483 with 5 procedural observations. Powered by Capital Market - Live News

Torrent Pharmaceuticals and Zydus Lifesciences announced that they have entered into a licensing and supply agreement to co-market Saroglitazar Mg for the treatment of Non-Alcoholic Steato Hepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD) in India. As the only approved drug for NASH and NAFLD in the country, Saroglitazar Magnesium is likely to play a key role in managing and mitigating these progressive and prevalent liver disorders. With a once daily, 4mg dose regimen, Saroglitazar Mg enables better compliance, reduces pill burden and offers greater convenience for patients.Under the terms of this agreement, Torrent will have semi-exclusive rights to co-market the product in India under the brand name VORXAR�. Zydus launched the drug under the brand names Lipaglyn� and Bilypsa� and will continue to market them. Torrent will pay Zydus upfront licensing fees and milestone payments based on the achievement of pre-defined milestones.Saroglitazar Mg, is an innovative drug from Zydus approved by the DCGI to treat chronic liver diseases such as, Non-Alcoholic Steato Hepatitis (NASH) and Non-Alcoholic Fatty Liver Disease (NAFLD). India is the first country to have a drug approved for these unmet medical needs. Currently, there is no approved drug for the treatment of NASH and NAFLD anywhere else in the world. Powered by Capital Market - Live News